OLD BRIDGE, NJ / ACCESSWIRE / March 25, 2019 / Blonder Tongue Laboratories, Inc. (NYSE American: BDR) announced today that it will report its Fourth Quarter 2018 Earnings Results on Monday, April 1, 2019 prior to market opening. Management will then host a teleconference to discuss the results with the investment community.

Details of the live teleconference:

Date: Monday, April 1, 2019
Time: 11:00 a.m. Eastern Time (10:00 a.m. CT, 8:00 a.m. PT)
Investor Dial-in (US & Canada Toll-Free): 844-369-8770

The audio replay will be available under Investor Related Information on the Blonder Tongue Investor Relations web page.

About Blonder Tongue

Blonder Tongue Laboratories, Inc. together with R. L. Drake Holdings, LLC – its wholly owned subsidiary – offer customers more than 130 years of combined engineering and manufacturing excellence with solid histories of delivering reliable, quality products. As a leader in the field of Cable Television Communications, the Company provides system operators and integrators serving the cable, broadcast, satellite, IPTV, institutional and professional video markets with comprehensive solutions for the provision of content contribution, distribution and video delivery to homes and businesses. The Company designs, manufactures, sells and supports an equipment portfolio of standard and high definition digital video solutions, as well as core analog video and high-speed data solutions for distribution over coax, fiber and IP networks. Additional information on the Company and its products can be found at www.blondertongue.com, and www.rldrake.com.

”Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The information set forth above includes ”forward-looking” statements and accordingly, the cautionary statements contained in Blonder Tongue’s Annual Report and Form 10-K for the year ended December 31, 2017 (See Item 1: Business, Item 1A: Risk Factors, Item 3: Legal Proceedings and Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations), and other filings with the Securities and Exchange Commission are incorporated herein by reference. The words ”believe,” ”expect,” ”anticipate,” ”project,” ”target,” ”intend,” ”plan,” ”seek,” ”estimate,” ”endeavor,” ”should,” ”could,” ”may” and similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to projections for our future financial performance, our anticipated growth trends in our business and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. Blonder Tongue undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Blonder Tongue’s actual results may differ from the anticipated results or other expectations expressed in Blonder Tongue’s ”forward-looking” statements.

Contacts

Eric Skolnik
Chief Financial Officer
eskolnik@blondertongue.com
(732) 679-4000

Robert J. Palle
Chief Executive Officer
bpalle@blondertongue.com
(732) 679-4000

SOURCE: Blonder Tongue Laboratories, Inc.

ReleaseID: 540055

13th Annual International Partnering Conference BIO-Europe Spring VIENNA
14th International Conference on Alzheimer’s and Parkinson’s Diseases (ADPD2019) LISBON

MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / March 25, 2019 / Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will continue its institutional presence in several reputed international conferences in the upcoming weeks.

Directors of the company will participate at the 13th Annual International Partnering Conference BIO-Europe Spring that will be held in Vienna, Austria, at the Messe Wien Exhibition and Congress Center, from March 25 to 27. BIO-Europe Spring is an annual event specialized in partnering and licensing alliances in the pharmaceutical sector.

Dr. Roger Bullock, Oryzon’s Medical Director and other directors of the company will also participate at the 14th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (ADPD2019) that takes in place in Lisbon, Portugal, from March 26 to 31. Dr. Bullock will present a poster communication entitled “Etheral: Vafidemstat in Alzheimer’s disease: design and baseline data” and an short oral presentation on Saturday, March 30, Auditorium V – SHORT ORAL SESSION 04.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds Vafidemstat and Iadademstat in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com

About Vafidemstat

Vafidemstat is an oral, brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule acts on several levels: it reduces cognitive impairment, memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies Vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer’s disease, to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, Vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has already started Phase IIa clinical studies with Vafidemstat in patients with Relapse-Remitting and Secondary Progressive MS (SATEEN), in patients with Mild to Moderate Alzheimer’s disease (ETHERAL) and in aggressiveness in patients with different psychiatric or neurodegenerative disorders (basket trial REIMAGINE).

About Iadademstat

Iadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (See Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A first Phase I/IIa clinical trial with Iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), medulloblastoma and others. Oryon has recently started two Phase IIa clinical trials of Iadademstat in combination; the first one in combination with Azacitidine in elderly AML patients (ALICE study) and the second one in combination with platinum/etoposide in second line SCLC patients (CLEPSIDRA study).

FORWARD-LOOKING STATEMENTS

This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

US Contact:

Spain:

Oryzon:

The Trout Group

ATREVIA

Emili Torrell

Thomas Hoffmann

Patricia Cobo/Idoia Revuelta

BD Director

+1 646 378 2932

+34 91 564 07 25

+34 93 515 13 13

thoffmann@troutgroup.com

pcobo@atrevia.com
irevuelta@atrevia.com

etorrell@oryzon.com

SOURCE: Oryzon Genomics, S.A.

ReleaseID: 540054

University Lending Group Now Largest Locally Based Lender In Ann Arbor Region

ANN ARBOR, MI / ACCESSWIRE / March 25, 2019 / University Bancorp, Inc. (OTCQB: UNIB) (the “Company” announced that University Lending Group (“ULG”, a subsidiary of University Bank (the “Bank” has acquired assets including leased branch offices and hired a group of 52 employees from Huron Valley Financial, Inc. (“HVF”, a privately held mortgage banking firm also headquartered in Ann Arbor, MI. The now allied group of employees on a combined basis was Washtenaw County’s #1 locally based first mortgage loan originator in both 2018 and 2017. In the transaction ULG also acquired assets and hired the employees of HVF’s reverse mortgage division, 1st Nations Reverse, and its wholesale lending division, HVF Partners. HVF was the #19 reverse mortgage lender nationwide in 2018 based on volume of loans originated.

The new associates add 26 retail residential loan officers, add 270 wholesale clients to its wholesale lending division, and ULG will instantly rank as one of the top reverse mortgage lenders in the country. The combined firm originated over $1 billion in residential first mortgages in 2017 and 2018. The combined firm will have over 440 employees, with the addition of 52 from the HVF team.

In Washtenaw County alone, the combined firm originated:

In 2017: 519 first mortgage loans for $116,981,869, 5.81% market share in units and 5.53% market share in dollars.
In 2018: 320 first mortgage loans for $77,474,554 4.46% market share in units and 4.16% market share in dollars.

In addition to its Ann Arbor headquarters, HVF also has Loan Production Branch Offices in Brighton, Clarkston and Southgate, which will be part of the combined firm. ULG also has offices in Ann
Arbor and Clinton Township, Michigan, as well as in Florida, Indiana, North Carolina and Texas.

The combined firm has the broadest portfolio of products of any lender in Washtenaw County, including conventional (FNMA, FHLMC, FHLB), government (FHA, VA, USDA-RD), reverse (FHA), single close construction to permanent financing, renovation (FNMA, FHLMC, FHA, VA), portfolio, jumbo, home equity, doctor and professional first time homebuyer and other niche products. The combined sales force can also refer customers as needed, to University Bank’s full community banking and insurance agency products (offered through Ann Arbor Insurance Centre*).

Stephen Lange Ranzini, President and CEO of University Bank stated, “I’ve known Eric Bradley prior to the foundation of HVF in 1997 and have admired his ability to build and bring together one of the top mortgage origination teams in Washtenaw County. We see this alliance and association as bringing together two very skilled teams with similar cultures. Both of our firms are focused on providing top rated customer service to consumers and specialize in working with sources of influence including Financial Advisors, CPAs, Lawyers and other professionals to provide professional mortgage services to their clients. We will bring our unique customer service that provides underwriting decisions and underwriting condition waivers in 24 hours or less and the wider product menu of financial services that University Bank makes available to this larger group of loan officers and their customers.”

Eric Bradley, President and CEO of Huron Valley Financial stated, “I am very pleased to unite the HVF team with University Bank and University Lending Group. I have known Stephen Lange Ranzini for over 22 years and I have always been impressed by his business acumen and his track record of success in growing the bank from $34 million in assets, $14 million in loans and 21 employees to $22 billion in assets under management and 390 employees. Integrating the unique mortgage loan products and services offered by both companies with our highly educated, professional, and ethical loan officers gives consumers in southeast Michigan a distinct choice for mortgage lenders. Our combined companies will offer a variety of unique products along with technology that allows consumers to manage the entire loan process online, yet we’ll still maintain local offices where consumers can meet in person with a mortgage professional and discuss financing options over a cup of coffee.

Eric Bradley and Stephen Lange Ranzini

The combined firm will be the largest locally based first mortgage loan originator. President Ranzini noted, ”We believe that consumers are better off dealing with local market experts who can provide personal service, attention and superior advice, and have access to a wider menu of financial services products that only a top rated community bank can provide.”

Addition details about the terms of the transaction are available on the Company’s investor relations web page at: http://www.university-bank.com/bancorp/.

Shareholders and investors are encouraged to refer to the financial information including the audited financial statements, strategic plan and prior press releases, available on our investor relations web page at: http://www.university-bank.com/bancorp/.

Ann Arbor-based University Bancorp owns 100% of University Bank which, together with its Michigan-based subsidiaries, holds and manages a total of over $22 billion in financial assets for over 127,000 customers, and our 440 employees make us the 5
th largest bank based in Michigan. University Bank is an FDIC-insured, locally owned and managed community bank, and meets the financial needs of its community through its creative and innovative services. Founded in 1890, University Bank® is the 15th oldest bank headquartered in Michigan. We are proud to have been selected as the “Community Bankers of the Year” by American Banker magazine and as the recipient of the American Bankers Association’s Community Bank Award. University Bank is a Member FDIC and an Equal Housing Lender. *(Insurance services are offered through Ann Arbor Insurance Centre, Inc. (AAIC), which is a wholly-owned subsidiary of University Bank. No FDIC Insurance/Risk of Loss: AAIC’s products are not insured by the FDIC or the Bank. AAIC’s products are not a deposit or other obligation of, or guaranteed by, the Bank).

The members of University Bank’s corporate family, ranked by their size of revenues are:

University Lending Group, a retail residential mortgage originator based in Clinton Township, MI;
Midwest Loan Services, a residential mortgage subservicer based in Houghton, MI;
UIF, a faith-based banking firm based in Southfield, MI;
Community Banking, based in Ann Arbor, MI, which provides traditional community banking services in the Ann Arbor & Washtenaw County area;
Midwest Loan Solutions, a residential mortgage correspondent lender based in Southfield, MI, also doing business as American Mortgage Solutions;
Ann Arbor Insurance Centre, an independent insurance agency based in Ann Arbor.

Contact: Stephen Lange Ranzini, President and CEO:

Phone: 734-741-5858, Ext. 9226

Email: ranzini@university-bank.com

CAUTIONARY STATEMENT: This press release contains certain forward-looking statements that involve risks and uncertainties. Forward-looking statements include, but are not limited to, statements concerning future changes in assets, pre-tax income, net income and budgeted income levels, the sustainability of past results, and other expectations and/or goals. Such statements are subject to certain risks and uncertainties which could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, economic, competitive, governmental, technological and legal factors affecting our operations, markets, products, services, interest rates and fees for services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

SOURCE: University Bancorp Inc.

ReleaseID: 539895

Reimbursement aligned with AHIP and CMS initiatives to help combat the opioid epidemic

ELMSFORD, NY / ACCESSWIRE / March 25, 2019 / NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it has begun receiving reimbursement approvals for PainShield® in the United States-market through commercial and workman’s compensation companies, in connection with American Health Insurance Plans (AHIP) and Centers for Medicare & Medicaid Services (CMS) programs designed to combat the opioid epidemic.

“AHIP is the largest and most active national association for healthcare coverage companies and CMS controls nearly all government healthcare payments,” said Brian Murphy, CEO of NanoVibronix. “Both AHIP and CMS have created and are mandating the use of Pain Management Plans, which encourage new technologies to address pain management. Working with insurance companies, in connection with AHIP and CMS, we have been able to secure approval and reimbursement for the use of the PainShield® technology based upon the proven effectiveness of PainShield®.”

“We are pleased with the market response to PainShield® by providers, who seek to provide effective alternative treatments, and payors, who are eager to assist with the early adoption of those treatments given the magnitude of the prescription opioid crisis in the U.S., which the Centers for Disease Control and Prevention recently reported at $78.5 billion annually,” continued Murphy. “The speed in which we secured reimbursement for PainShield® is extremely gratifying and further validates the overall market need and acceptance of our product, which is supported by strong clinical data. With PainShield®, we have been able to pair a highly effective treatment modality with a corresponding national initiative to address the opioid crisis. We are well positioned to provide vital and safe treatments to patients, while assisting payors and providers to comply with new regulations.”

About NanoVibronix

NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave technology. The company’s technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including the disruption of biofilms and bacteria colonization, as well as providing pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield®, UroShield™ and WoundShield™. Additional information about the company is available at: www.nanovibronix.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital may not be available, or may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications
naov@crescendo-ir.com
(212) 671-1021

SOURCE: NanoVibronix, Inc.

ReleaseID: 540042

JUPITER, FL / ACCESSWIRE / March 25, 2019 / Dyadic International, Inc. (the “Company”) (OTCQX: DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb and Chief Accounting Officer, Ping Rawson will be presenting at the following three upcoming investor conferences:

Sidoti & Company Spring Conference – Presenter – Mark Emalfarb
New York City, NY
Thursday, March 28, 2019
12:55 p.m. ET

MicroCap Spring Summit – Presenter – Ping Rawson
New York City, NY
Monday, April 1, 2019
1:30 p.m. ET Track 1

OTCQX Virtual Investor Conference – Presenter – Mark Emalfarb
Thursday, April 4, 2019
11:30 a.m. ET

Mr. Emalfarb and Mrs. Rawson will be available during the events in NYC for one-on-one meetings with institutional analysts and investors. For more information on the conference or to schedule a one-on-one meeting with Mr. Emalfarb or Mrs. Rawson, please contact Dyadic at (561) 743-8333 or send us an email to prawson@dyadic.com

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large-scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies for their potential use in the development and manufacture of human and animal biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic’s website at http://www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and historical financial reports for Dyadic in the Company’s annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies’ willingness to adopt, utilize and approve the use of the C1 gene expression platform; and (9) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in our Form 10 filed with the SEC on February 8, 2019, our December 31, 2017 Annual Report filed with the OTC Markets on March 27, 2018, and our September 30, 2018 Quarterly Report filed with the OTC Markets on November 8, 2018, and our other filings with the SEC which are available at the SEC’s internet site (http://www.sec.gov). New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.

Contact:

Dyadic International, Inc.
Ping Rawson
Chief Accounting Officer
Phone: 561-743-8333
Email: prawson@dyadic.com

SOURCE: Dyadic International, Inc.

ReleaseID: 540052

With the Help of Evzo.com, People Across the U.S. and Canada Can Find the Best Professional to Help with their Specific Needs

LOS ANGELES, CA / ACCESSWIRE / March 25, 2019 / The founders of Evzo.com, a website that helps connect consumers from the United States and Canada with the best professionals in their local area, are pleased to announce the launch of their new and user-friendly website.

To learn more about Evzo.com and see how the new site works, please visit https://www.evzo.com/.

As a company spokesperson noted, the founders of Evzo.com understand that when people need to find professionals like doctors, lawyers or contractors, calling friends and family members for referrals can be a very time consuming process. In addition, searching dozens of professional websites can also take hours, and can leave consumers feeling overwhelmed.

This knowledge inspired the founders to create and launch Evzo.com, and provide people from across the United States and Canada with a comprehensive and easy-to-navigate database of millions of professionals. From people who are looking for a doctor to help them with a health concern and those who would like to hire a lawyer to assist with a legal matter to people who would like to tackle some home improvements and are searching for contractors to call in their city, Evzo.com is a one-stop professional resource shop.

“Our team works relentlessly to update and expand a wide selection of experts from hundreds of sources and to provide you the best user experience,” the spokesperson noted, adding that currently, Evzo.com is focusing on the health, legal and home improvement niches.

For example, for those who are looking for a doctor, Evzo.com will allow consumers to select from a comprehensive list of certified medical, dentistry and aesthetic professionals covered by their insurance plan, who are also conveniently located and accepting new patients.

Even through Evzo.com just recently launched, it is already creating quite a positive buzz with both consumers and professionals. Already, over 5 million professionals are listed on the website, and consumers can read over 1 million reviews of their services.

About Evzo.com:

Evzo.com is a new website that helps people from across the U.S. and Canada find the right professional to help solve problems that require real expertise. The site focuses on the health, legal and home improvement niches, and makes it easy for consumers to find doctors, lawyers and contractors in their local area. For more information, please visit https://www.evzo.com/.

Contact:

Elena Alexander

hello@evzo.com

1-833-568-3896

SOURCE: Evzo.com

ReleaseID: 540048

Philadelphia PD one of nine additional departments to complete Wrap’s ‘Train the Trainer’ program

LAS VEGAS, NV / ACCESSWIRE / March 25, 2019 / Wrap Technologies, Inc. (the “Company”) (NASDAQ: WRTC), an innovator of modern policing solutions, today reported that trainers from the Philadelphia Police Department and eight other departments across the country have completed ‘Train the Trainer’ sessions since the Company’s last report released mid-February.

52 police departments across the U.S. have now received training; 202 of their trainers are now certified BolaWrap 100 instructors and can train other officers.

Philadelphia Police Department is the nation’s fourth largest police department with 6,300 sworn members, and initially plans to train and equip more than 50 officers with the BolaWrap.

“We are continuing to see positive responses from our training sessions and excitement about deploying the BolaWrap in the field,” said Lee Leatherman, Director of Training at Wrap Technologies.

Wrap Technologies’ recent hire, Rick Guilbault, founder of TASER International’s Training Academy, has assembled a team of 5 experienced and well-known trainers from different regions across the U.S. to form the Wrap Training Academy Advisory Board.

“The Wrap Training Academy Advisory Board will provide guidance in creating and maintaining a world class training program for Wrap Technologies. We are excited to be working with some of the top law enforcement trainers in the country, and we are honored that they have agreed to share their diverse knowledge and experience to keep Wrap Technologies on the cutting edge of law enforcement training,” said Mr. Guilbault, VP of Training at Wrap Technologies.

Additionally, Mr. Guilbault has instituted a strategic development in the Company’s goal to streamline the BolaWrap’s sales cycle. Master Trainers from the Company, in addition to Company executives, will now be attending demonstrations of the BolaWrap at police departments across the country in order to facilitate conversation with line level trainers during the demonstrations themselves.

About Wrap Technologies (WRTC)

Wrap Technologies is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to entangle an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. For information on the Company please visit www.wraptechnologies.com. Examples of recent media coverage are available as links under the “Media” tab of the website.

Trademark Information: BolaWrap is a registered trademark of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company’s overall business, total addressable market and expectations regarding future sales and expenses. Words such as “expect,” “plan,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors included in the Company’s most recent quarterly report on Form 10-Q and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

WRAP TECHNOLOGIES’ CONTACT:
Investor Relations
800-583-2652, Ext #515
IR@wraptechnologies.com

SOURCE: Wrap Technologies, Inc.

ReleaseID: 540041

Reddiquette.com Includes a Complete Guide to Reddit Advertising, Advice on How to Get Started and Much More

LOS ANGELES, CA / ACCESSWIRE / March 25, 2019 / The founders of Reddiquette.com, a website that is devoted to helping people who want to learn more about Reddit ads, are pleased to announce the launch of their new and user-friendly website.

To check out the new site and read one of the new articles, titled “Reddit Ads: The Complete (Updated) Guide,” please visit https://www.reddiquette.com/getting-started-with-reddit-ads/.

As a spokesperson for Reddiquette.com noted, the founders of the website understand that while many people have heard of Reddit advertising and marketing, they may be unsure if it’s something they should pursue or how to go about it. Since Reddit is also a relatively underutilized advertising platform, the founders know that there is not a lot of information out there that explains about Reddit marketing and ads.

This inspired them to launch Reddiquette.com, and provide people with a one stop Reddit ad shop.

Even though the site was only launched just recently, it is already getting a lot of positive attention from visitors to the site. For example, the guide about Reddit ads is creating a lot of buzz with readers who are hungry for information on the topic.

As the guide notes, Reddit offers far more value for the money and a higher potential ceiling, when used properly, than Facebook and Instagram.

“There is no other platform that gives access to a highly targeted audience in the same way that Reddit does,” the guide notes, adding that while Reddit can be more difficult to effectively navigate, and it may seem more confusing than other social media platforms, once these basics are learned, it can become an immeasurably powerful tool in a marketing strategy.

For those who are still unsure if Reddit ads are right for them and their company, the guide also offers a handy list of pros and cons. One key pro, the guide notes, is that Reddit offers a huge range of active users that business owners can target.

“The opportunities afforded by Reddit are vast because the traffic can be so segmented, as the use of ‘subreddits’ can allow you to find a new marketing opportunity that your competition may have missed,” the guide notes.

About Reddiquette.com:

Reddiquette.com is a new website that features in-depth and helpful information and advice about Reddit advertising and marketing. The site includes guides, advice on why people would want to use Reddit ads, tips on how to get started and much more. For more information, please visit https://www.reddiquette.com/.

Contact:

Freddie Boyd
admin@rocketfactor.com
(949) 555-2861

SOURCE: Reddiquette

ReleaseID: 540045

ANAHEIM HILLS, CA / ACCESSWIRE / March 25, 2019 / Heads Up Checkup, Inc., an emerging SAAS provider of mental health and behavioral risk screening systems, today announced that it will be presenting at the 146th NIBA Investment Conference being held on March 25-26, 2019 at Crown Plaza Times Square in New York City. Martin Eaton, Founder and CEO, will be presenting, as well as meeting with investment professionals.

About NIBA

For over 38 years NIBA has been serving the micro-cap and small-cap investment community and has hosted 145 investment conferences. NIBA network firms have successfully completed thousands of transactions totaling over $17 billion in new capital for emerging growth companies and are responsible for 90% of all IPOs under $20 million. NIBA’s network is comprised of thousands of investment professionals representing over 60 key industry services and includes over 8,800 registered representatives that have over $78 billion assets under management.

About Heads Up Checkup, Inc.

Heads Up Checkup, Inc. is a SaaS provider of web-based and mobile solutions for universal mental health and behavioral risk screening. The company has developed a proactive solution for school and workplace safety to address a $1billion+ market opportunity. The screening system is designed to accelerate the identification of individuals in crisis and shorten the time to treatment – before acts of self-harm or violence occur. Frequent and widespread use in schools, healthcare, and the workplace would have an unprecedented positive impact on our society, fiscally and socially.

Heads Up Checkup is the only mental health and behavioral risk screening system on the market that is cloud-based, comprehensive, self-scoring and reporting, offers de-identified aggregated data to inform mental health trends, and connects user to support resources in real time. Heads Up Checkup’s addressable market consists of: schools concerned with safety, consistent student attendance, and student success, businesses concerned with safety and productivity, healthcare and health insurance companies concerned about the rising costs of treating mental ill health as well as the negative effects of mental illness on physical health, nonprofit organizations serving the mentally ill concerned about fast and cost-effective screening. For more information, please visit the website at www.headsupcheckup.com.

Safe Harbor Statement

This press release may contain forward-looking statements, including information about management’s view of Heads Up Check Up, Inc. (”the Company”), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words ”believes,” ”expects,” ”intends,” ”plans,” ”anticipates,” or ”may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Heads Up Check Up, Inc.

News Compliments of ACCESSWIRE.

Heads Up Checkup, Inc.

Contact:

Martin Eaton

CEO

Heads Up Checkup, Inc.

Email: info@headsupcheckup.com

Main: 714.716.1617

SOURCE: Heads Up Checkup, Inc.

ReleaseID: 539794

NEW YORK, NY / ACCESSWIRE / March 25, 2019 / Palladion Signature Import (PSI) Limited, an emerging luxury Fine Wines & Premium Spirits Importer, is presenting at the 146th NIBA Investment Conference, March 25th-26th, Crown Plaza Times Square in New York City. Billy Starkey, PSI’s CEO, is presenting.

For more information about NIBA or participating in the upcoming New York Conference on March 25th-26th, 2019, please visit www.nibanet.org or contact NIBA at emily@nibanet.org or 706-208-9620.

About Palladion Signature Import (PSI) Limited.

Palladion Signature Import (PSI) is a high-end fine wines & premium spirits importer specializing in the exclusive import of small batch, traditionally handcrafted, artisanal products – capitalizing on underserved nationwide demand for non-mainstream specialties at top-tier market segments. Key components of PSI’s strategy include securing exclusivities with independent family-estate producers of top expert-vetted products, and building these brands globally through disciplined high-end placements.

Corporate-owned multi-state top-tier venues and fine dining restaurants add to the demand for PSI’s exclusive product lines within this surging market segment. This segment lies beyond the reach of localized boutique importers and is underserved by large suppliers that favor high volume “power brand” industrialized products. During proof of concept and market testing, PSI’s product lines were swiftly adopted by key corporate customers including MGM International, Caesars Entertainment, Hakkasan Group, and Darden Group, the world’s largest table service restaurant corporation. In addition, PSI swiftly added independent Michelin-starred restaurants and renowned VIP venues including the Embassy of France, the Residence of the Ambassador of France, and the Embassy of Italy.

PSI serves another unique industry role, but on the supply side. By its introduction and development of these family-estate brands to the US, PSI greatly aids the preservation of precious traditional craft methodologies – arts that are rapidly disappearing as cost-cutting industrial methods overtake the global landscape and erode overall product quality across the industry. Master-level clients recognize PSI’s quality and rarity, which further propels top-tier demand for PSI’s exclusive product lines.

About NIBA

For over 38 years NIBA has been serving the micro-cap and small-cap investment community and has hosted 145 investment conferences. NIBA network firms have successfully completed thousands of transactions totaling over $17 billion in new capital for emerging growth companies and are responsible for 90% of all IPOs under $20 million. NIBA’s network is comprised of thousands of investment professionals representing over 60 key industry services and includes over 8,800 registered representatives that have over $78 billion assets under management.

For more information please visit our website at www.nibanet.org and, again, we look forward to having you with us at NIBA New York

News Compliments of ACCESSWIRE.

Contact:

Billy Starkey, CEO, Palladion Signature Import (PSI)
Email: contact@palladionimport.com
Direct: (540) 547-7771
Main : (540) 547-7778
Fax: (540) 547-7779

SOURCE: Palladion Signature Import (PSI)

ReleaseID: 539825